FDA Proposes To Strengthen Label Warning For Xolair
Mon, 26 Feb 2007 09:00 PM EST
... Today the Food and Drug Administration (FDA) announced that it has requested Genentech, Inc. add a boxed warning to the product label for omalizumab, marketed as Xolair. The boxed warning emphasizes that Xolair, used to treat patients with asthma related to allergies, may cause anaphylaxis. [click link for full article] ...
Related Topics
- Food Labels
- Omalizumab
- Tacrolimus ointment
- Pimecrolimus Cream 1%
- Rofecoxib
- Amphetamine and Dextroamphetamine ER
- Surgeon General's Reports on Tobacco
- Mammography
- Carcinogens
- Immune System
- Dietary Guidelines
- Thalidomide
- Ibuprofen Suspension
- Machine Safety
- Hazardous Waste
- Electrical Safety
- Salmeterol Aerosol Inhalation
- Brain Tumor, Childhood
- Food Labeling
- Alcoholism

Not Signed In -


